Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nagano, N.
Right arrow Articles by Wada, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagano, N.
Right arrow Articles by Wada, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1870-1878
© 2001 European Renal Association-European Dialysis and Transplant Association

Sevelamer hydrochloride (Renagel®), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency

Nobuo Nagano1,, Sonoe Miyata1, Sachiko Obana1, Masako Ozai1, Nami Kobayashi1, Naoshi Fukushima2, Steven K. Burke3 and Michihito Wada1

1 Pharmaceutical Development Laboratories, Kirin Brewery Co., Ltd, Takasaki, 2 Fuji Gotenba Research Laboratory, Chugai Pharmaceutical Co., Ltd, Shizuoka, Japan, and 3 GelTex Pharmaceuticals, Inc., Massachusetts, USA

Background. It has been demonstrated that dietary phosphate restriction suppresses parathyroid hormone (PTH) secretion and parathyroid cell proliferation in experimental animals with chronic renal insufficiency (CRI) independently of serum calcium and 1,25(OH)2D3 levels. This study was conducted to examine whether sevelamer hydrochloride (Renagel®; hereafter referred to as sevelamer), a non-calcaemic phosphate binder could inhibit the parathyroid gland (PTG) hyperplasia in rats with progressive CRI.

Methods. Male Sprague–Dawley rats were injected twice with low doses of adriamycin (ADR). Two weeks after the last injection of ADR, rats were fed a diet containing 1 or 3% sevelamer for 84 days. Time course changes of serum levels of calcium, phosphorus, and PTH were measured. At the end of study, serum 1,25(OH)2D3 levels were measured and the maximal two-dimension area of the PTG in paraffin section was calculated using an imaging analyser.

Results. Dietary sevelamer treatment inhibited the elevations of serum phosphorus, calciumxphosphorus product, and PTH levels that occurred as the study progressed. Sevelamer also suppressed maximal PTG area and there existed positive strong correlation between maximal PTG area and serum PTH levels at the end of the study. Serum phosphorus levels positively correlated well with serum PTH levels and maximal PTG area. In contrast, serum calcium or 1,25(OH)2D3 levels did not show any correlation with serum PTH levels and maximal PTG area.

Conclusions. Sevelamer treatment arrested hyperphosphataemia and PTG hyperplasia accompanied by the elevation of serum PTH levels. The correlation analysis suggests that reduced serum phosphorus levels contributed to the suppression of PTG hyperplasia and resulted in the reduction of PTH levels in this animal model after the sevelamer treatment. The management of phosphorus control started from early stage of CRI could prevent PTG hyperplasia and facilitate later management of secondary hyperparathyroidism.

Keywords: parathyroid hormone (PTH); parathyroid-gland hyperplasia; phosphate binder; serum phosphorus; sevelamer hydrochloride (Renagel®)

Nobuo Nagano PhD, Pharmaceutical Development Laboratories, Kirin Brewery Co., Ltd, 3 Miyahara-cho, Takasaki-shi, Gunma 370-1295, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
N. Nagano, S. Miyata, M. Abe, S. Wakita, N. Kobayashi, and M. Wada
Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 634 - 643.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
T. Kawata, Y. Imanishi, K. Kobayashi, T. Kenko, M. Wada, E. Ishimura, T. Miki, N. Nagano, M. Inaba, A. Arnold, et al.
Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism
Eur. J. Endocrinol., October 1, 2005; 153(4): 587 - 594.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
N. Nagano, S. Miyata, S. Obana, N. Kobayashi, N. Fukushima, S. K. Burke, and M. Wada
Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency
Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2014 - 2023.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
N. Nagano, S. Miyata, S. Obana, N. Kobayashi, M. Abe, N. Fukushima, and M. Wada
Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii81 - 85.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.